Ost-müük Eiger Biopharma - EIGR CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | - | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eiger BioPharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Eelmine sulgemine* | N/A |
Avatud* | N/A |
Aastane muutus* | N/A |
Päeva ulatus* | N/A |
52 nädala ulatus | 0.75-9.89 |
Keskmine maht (10 päeva) | 311.24K |
Keskmine maht (3 kuud) | 7.27M |
Turukapitalisatsioon | 50.94M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 44.30M |
Tulu | 14.93M |
EPS | -2.21 |
Dividendid (% kasumist) | N/A |
Beeta | 1.85 |
Järgmine tuluaruande kuupäev | Aug 2, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|
Eiger Biopharma Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Thursday, June 15, 2023 | ||
Kellaaeg (UTC) (UTC) 17:00 | Riik US
| Sündmus Eiger BioPharmaceuticals Inc Annual Shareholders Meeting Eiger BioPharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, August 2, 2023 | ||
Kellaaeg (UTC) (UTC) 20:00 | Riik US
| Sündmus Q2 2023 Eiger BioPharmaceuticals Inc Earnings Release Q2 2023 Eiger BioPharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 1, 2023 | ||
Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 Eiger BioPharmaceuticals Inc Earnings Release Q3 2023 Eiger BioPharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 13.484 | 12.142 | 0 | 0 | 0 |
Tulu | 13.484 | 12.142 | |||
Kogu tegevuskulu | 107.324 | 89.081 | 62.149 | 68.904 | 51.047 |
Müük/Üldine/admin kulud, kokku | 29.105 | 23.9 | 20.559 | 17.113 | 13.956 |
Uuringud ja arendus | 75.282 | 64.436 | 41.59 | 51.791 | 37.091 |
Tulud majandustegevusest | -93.84 | -76.939 | -62.149 | -68.904 | -51.047 |
Intressitulud (kulu), muud tulud, neto | -3.05 | -3.401 | -2.89 | -1.333 | -1.332 |
Muud, neto | 0.137 | 46.487 | -0.012 | -0.015 | -0.012 |
Netotulu enne makse | -96.753 | -33.853 | -65.051 | -70.252 | -52.391 |
Netotulu pärast makse | -96.776 | -33.917 | -65.051 | -70.252 | -52.391 |
Netotulu enne erikulusid | -96.776 | -33.917 | -65.051 | -70.252 | -52.391 |
Netotulu | -96.776 | -33.917 | -65.051 | -70.252 | -52.391 |
Arvestatav tulu, v a erikulud | -96.776 | -33.917 | -65.051 | -70.252 | -52.391 |
Arvestatav tulu, koos erikuludega | -96.776 | -33.917 | -65.051 | -70.252 | -52.391 |
Jaotamisele kuuluv netotulu | -96.776 | -33.917 | -65.051 | -70.252 | -52.391 |
Keskmine jaotamisele kuuluv aktsia kohta | 41.6282 | 33.9443 | 28.1434 | 22.7856 | 13.711 |
Jaotatav EPS, v a erakorralised kulud | -2.32477 | -0.99919 | -2.31141 | -3.08317 | -3.82108 |
Jaotamisele kuuluv normaal-EPS | -2.30759 | -0.99919 | -2.31141 | -3.08317 | -3.82108 |
Kulud, Kokku | 1.837 | 0.745 | |||
Brutokasum | 11.647 | 11.397 | |||
Ootamatud kulutused (tulu) | 1.1 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 4.118 | 2.696 | 4.024 | 4.091 | 2.673 |
Tulu | 4.118 | 2.696 | 4.024 | 4.091 | 2.673 |
Kulud, Kokku | 0.108 | 0.345 | 1.231 | 0.151 | 0.11 |
Brutokasum | 4.01 | 2.351 | 2.793 | 3.94 | 2.563 |
Kogu tegevuskulu | 26.381 | 27.167 | 30.393 | 25.271 | 24.493 |
Müük/Üldine/admin kulud, kokku | 9.515 | 8.301 | 6.964 | 7.027 | 6.813 |
Uuringud ja arendus | 16.748 | 18.521 | 22.198 | 16.993 | 17.57 |
Tulud majandustegevusest | -22.263 | -24.471 | -26.369 | -21.18 | -21.82 |
Intressitulud (kulu), muud tulud, neto | -0.574 | -0.751 | -0.745 | -0.713 | -0.841 |
Gain (Loss) on Sale of Assets | |||||
Muud, neto | 0.055 | 0.081 | 0.003 | 0.026 | 0.027 |
Netotulu enne makse | -22.782 | -25.141 | -27.111 | -21.867 | -22.634 |
Netotulu pärast makse | -22.784 | -25.138 | -27.111 | -21.884 | -22.643 |
Netotulu enne erikulusid | -22.784 | -25.138 | -27.111 | -21.884 | -22.643 |
Netotulu | -22.784 | -25.138 | -27.111 | -21.884 | -22.643 |
Arvestatav tulu, v a erikulud | -22.784 | -25.138 | -27.111 | -21.884 | -22.643 |
Arvestatav tulu, koos erikuludega | -22.784 | -25.138 | -27.111 | -21.884 | -22.643 |
Jaotamisele kuuluv netotulu | -22.784 | -25.138 | -27.111 | -21.884 | -22.643 |
Keskmine jaotamisele kuuluv aktsia kohta | 44.1456 | 44.0931 | 44.0106 | 43.0598 | 35.2532 |
Jaotatav EPS, v a erakorralised kulud | -0.51611 | -0.57011 | -0.61601 | -0.50822 | -0.6423 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.51596 | -0.57011 | -0.61601 | -0.49162 | -0.6423 |
Ootamatud kulutused (tulu) | 0.01 | 0 | 1.1 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 117.535 | 103.364 | 137.806 | 100.384 | 101.845 |
Raha ja lühiajalised investeeringud | 98.948 | 88.815 | 128.84 | 94.994 | 100.353 |
Raha ja ekvivalendid | 25.798 | 22.221 | 28.864 | 39.373 | 61.262 |
Lühiajalised investeeringud | 73.15 | 66.594 | 99.976 | 55.621 | 39.091 |
Prepaid Expenses | 13.985 | 9.361 | 8.966 | 5.39 | 1.492 |
Total Assets | 120.139 | 126.402 | 143.594 | 105.139 | 102.448 |
Property/Plant/Equipment, Total - Net | 1.257 | 1.266 | 1.885 | 2.244 | 0.167 |
Property/Plant/Equipment, Total - Gross | 2.152 | 1.869 | 2.227 | 2.458 | 0.328 |
Accumulated Depreciation, Total | -0.895 | -0.603 | -0.342 | -0.214 | -0.161 |
Other Long Term Assets, Total | 1.347 | 4.51 | 3.903 | 2.511 | 0.436 |
Total Current Liabilities | 25.121 | 29.901 | 16.627 | 16.949 | 10.024 |
Accounts Payable | 8.975 | 7.765 | 4.64 | 6.414 | 5.83 |
Accrued Expenses | 16.146 | 14.327 | 11.987 | 10.535 | 4.194 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 64.829 | 54.003 | 48.559 | 48.659 | 35.856 |
Total Long Term Debt | 39.625 | 23.986 | 31.194 | 30.39 | 25.62 |
Long Term Debt | 39.625 | 23.986 | 31.194 | 30.39 | 25.62 |
Other Liabilities, Total | 0.083 | 0.116 | 0.738 | 1.32 | 0.212 |
Total Equity | 55.31 | 72.399 | 95.035 | 56.48 | 66.592 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.044 | 0.035 | 0.034 | 0.024 | 0.019 |
Additional Paid-In Capital | 492.759 | 412.93 | 401.509 | 297.863 | 237.795 |
Retained Earnings (Accumulated Deficit) | -437.193 | -340.417 | -306.5 | -241.449 | -171.197 |
Other Equity, Total | -0.3 | -0.149 | -0.008 | 0.042 | -0.025 |
Total Liabilities & Shareholders’ Equity | 120.139 | 126.402 | 143.594 | 105.139 | 102.448 |
Total Common Shares Outstanding | 44.0743 | 34.5688 | 33.8785 | 24.5234 | 19.2118 |
Current Port. of LT Debt/Capital Leases | 0 | 7.809 | 0 | ||
Laekumata arved, neto | 1.749 | 2.576 | |||
Accounts Receivable - Trade, Net | 1.749 | 2.576 | |||
Total Inventory | 2.853 | 2.612 | |||
Long Term Investments | 0 | 17.262 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 96.911 | 117.535 | 142.289 | 157.703 | 147.356 |
Raha ja lühiajalised investeeringud | 75.272 | 98.948 | 121.044 | 141.792 | 132.717 |
Raha ja ekvivalendid | 15.181 | 25.798 | 26.308 | 36.572 | 46.562 |
Lühiajalised investeeringud | 60.091 | 73.15 | 94.736 | 105.22 | 86.155 |
Laekumata arved, neto | 3.891 | 1.749 | 2.458 | 1.038 | 2.287 |
Accounts Receivable - Trade, Net | 3.891 | 1.749 | 2.458 | 1.038 | 2.287 |
Total Inventory | 5.338 | 2.853 | 2.817 | 2.876 | 1.91 |
Prepaid Expenses | 12.41 | 13.985 | 15.97 | 11.997 | 10.442 |
Total Assets | 99.228 | 120.139 | 143.744 | 163.691 | 153.329 |
Property/Plant/Equipment, Total - Net | 1.25 | 1.257 | 0.757 | 0.91 | 1.066 |
Other Long Term Assets, Total | 1.067 | 1.347 | 0.698 | 5.078 | 4.907 |
Total Current Liabilities | 23.999 | 25.121 | 26.119 | 21.847 | 36.612 |
Accounts Payable | 11.858 | 8.975 | 10.497 | 9.945 | 9.218 |
Accrued Expenses | 12.141 | 16.146 | 15.622 | 11.902 | 14.845 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 63.989 | 64.829 | 65.436 | 60.766 | 56.062 |
Total Long Term Debt | 39.989 | 39.625 | 39.315 | 38.916 | 19.446 |
Long Term Debt | 39.989 | 39.625 | 39.315 | 38.916 | 19.446 |
Other Liabilities, Total | 0.001 | 0.083 | 0.002 | 0.003 | 0.004 |
Total Equity | 35.239 | 55.31 | 78.308 | 102.925 | 97.267 |
Common Stock | 0.044 | 0.044 | 0.044 | 0.044 | 0.041 |
Additional Paid-In Capital | 495.342 | 492.759 | 490.939 | 488.586 | 460.808 |
Retained Earnings (Accumulated Deficit) | -459.977 | -437.193 | -412.055 | -384.944 | -363.06 |
Other Equity, Total | -0.17 | -0.3 | -0.62 | -0.761 | -0.522 |
Total Liabilities & Shareholders’ Equity | 99.228 | 120.139 | 143.744 | 163.691 | 153.329 |
Total Common Shares Outstanding | 44.2964 | 44.0743 | 44.048 | 43.9668 | 40.5298 |
Long Term Investments | 0 | 0 | 0 | 0 | |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 12.549 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -96.776 | -33.917 | -65.051 | -70.252 | -52.391 |
Raha majandustegevusest | -83.01 | -71.342 | -63.185 | -63.614 | -42.671 |
Raha majandustegevusest | 0.292 | 0.276 | 0.167 | 0.068 | 0.054 |
Mittelikviidsed varad | 12.993 | -36.079 | 7.596 | 6.579 | 5.601 |
Muutused tööjõus | 0.481 | -1.622 | -5.897 | -0.009 | 4.065 |
Tulu investeeringutelt | 9.632 | 61.532 | -44.787 | -16.471 | -29.085 |
Kapitalikulutused | -0.34 | -0.225 | -0.258 | -0.475 | -0.142 |
Muud rahavood investeeringutelt, kokku | 9.972 | 61.757 | -44.529 | -15.996 | -28.943 |
Rahavood investeeringutelt | 76.955 | 3.167 | 97.463 | 58.196 | 100.983 |
Aktsiate emiteerimine (tagasiost), neto | 71.793 | 3.658 | 97.485 | 54.168 | 91.048 |
Laenu väljastamine (kustutamine), neto | 5.448 | -0.175 | 0 | 4.96 | 9.935 |
Rahaline kogumuutus | 3.577 | -6.643 | -10.509 | -21.889 | 29.227 |
Makstud intressid | 2.885 | 2.783 | 2.791 | 2.638 | 1.652 |
Rahavoogudesse investeerimine | -0.286 | -0.316 | -0.022 | -0.932 | |
Cash Taxes Paid | 0.064 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -22.784 | -96.776 | -71.638 | -44.527 | -22.643 |
Cash From Operating Activities | -24.005 | -83.01 | -60.763 | -40.203 | -18.459 |
Cash From Operating Activities | 0.074 | 0.292 | 0.219 | 0.146 | 0.073 |
Non-Cash Items | 2.657 | 12.993 | 10.655 | 6.718 | 2.728 |
Cash Interest Paid | 0.92 | 2.885 | 2.038 | 1.395 | 0.686 |
Changes in Working Capital | -3.952 | 0.481 | 0.001 | -2.54 | 1.383 |
Cash From Investing Activities | 13.383 | 9.632 | -12.165 | -22.549 | -3.002 |
Capital Expenditures | -0.216 | -0.34 | -0.116 | -0.009 | 0 |
Other Investing Cash Flow Items, Total | 13.599 | 9.972 | -12.049 | -22.54 | -3.002 |
Cash From Financing Activities | 0.041 | 76.955 | 77.015 | 77.103 | 45.802 |
Financing Cash Flow Items | 0 | -0.286 | -0.244 | -0.244 | -0.016 |
Issuance (Retirement) of Stock, Net | 0.041 | 71.793 | 71.75 | 71.619 | 45.818 |
Issuance (Retirement) of Debt, Net | 5.448 | 5.509 | 5.728 | 0 | |
Net Change in Cash | -10.617 | 3.577 | 4.087 | 14.351 | 24.341 |
Cash Taxes Paid | 0 | 0.064 | 0.043 | 0.152 | 0.041 |
Foreign Exchange Effects | -0.036 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 17.266 | 7648219 | 2571876 | 2023-03-31 | LOW |
Arkin (Moshe) | Individual Investor | 10.1185 | 4482126 | 1769124 | 2023-04-10 | LOW |
683 Capital Management LLC | Hedge Fund | 8.9172 | 3950000 | 835000 | 2023-03-31 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.7933 | 2566229 | -43596 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.8952 | 2168404 | 105783 | 2023-03-31 | LOW |
Propel Bio Partners L.P. | Venture Capital | 2.4825 | 1099653 | 0 | 2023-04-30 | HIGH |
Simplify Asset Management Inc | Investment Advisor | 2.4825 | 1099653 | 1099653 | 2023-03-31 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.8896 | 837003 | 27528 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7783 | 787735 | 27428 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.0558 | 467682 | 160382 | 2023-03-31 | HIGH |
Medical Strategy GmbH | Investment Advisor | 0.9682 | 428873 | 44000 | 2023-01-31 | LOW |
UBS O'Connor LLC | Hedge Fund | 0.9529 | 422102 | -50000 | 2023-03-31 | HIGH |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.9139 | 404820 | -201668 | 2023-03-31 | LOW |
Columbia Threadneedle Investments (UK) | Investment Advisor/Hedge Fund | 0.8563 | 379313 | 10900 | 2023-03-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7824 | 346575 | -2006 | 2023-03-31 | LOW |
Telemetry Investments, L.L.C. | Hedge Fund | 0.7788 | 345000 | 166500 | 2022-12-31 | HIGH |
Glenn (Jeffrey Scott) | Individual Investor | 0.765 | 338879 | 6000 | 2023-03-20 | |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.6377 | 282471 | -208017 | 2023-03-31 | MED |
Goldman Sachs & Company, Inc. | Research Firm | 0.5526 | 244783 | 107294 | 2023-03-31 | MED |
ACT Capital Management, L.L.C. | Hedge Fund | 0.5305 | 235000 | -15000 | 2022-09-30 | MED |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group530K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$46M+
Igakuine investeerimise maht
$31M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Eiger Biopharma Company profile
Ettevõttest Eiger Biopharma
Eiger BioPharmaceuticals, Inc. on kommertsjärgus biofarmatseutiline ettevõte. Ettevõte keskendub raskete haiguste ravimite väljatöötamisele ja turustamisele. Tema juhtivad kliinilised programmid keskenduvad hepatiidi deltaviiruse (HDV), viirusliku hepatiidi raske vormi ravi arendamisele. Tema kliiniliste tootekandidaatide hulka kuuluvad Lonafarnib (LNF) HDV puhul, Peginterferon Lambda (lambda) HDV puhul, Avexitide postbariaatrilise hüpoglükeemia (PBH) ja Avexitide kaasasündinud hüperinsulinismi (CHI) puhul. LNF on suukaudselt biosaadav farnesüülimise inhibiitor, mis on III faasi kliinilises uuringus HDV-infektsiooni puhul. Lambda on III tüüpi interferoon (IFN), mis stimuleerib immuunvastust, mis on kriitilise tähtsusega peremeesorganismi kaitse arendamiseks viirusinfektsioonide ajal. Avexitiid on peptiid, mida arendatakse PBH raviks. Avexitiid on mõeldud kaasasündinud hüperinsulinismi (CHI), pediaatrilise ainevahetushäire raviks.
Industry: | Biotechnology & Medical Research (NEC) |
2155 Park Blvd
PALO ALTO
CALIFORNIA 94306-1543
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com